Wanbury

₹201.00As of Sun 8 Nov 2026, 12:00 UTC

NSE:WANBURYHealthcare

Country India

PE (Fwd) 10.25

TSR 10Y CAGR 14.68%

Div yield —

ROE —

Drug Manufacturers (Specialty & Generic)

Beta (5Y) 0.18

PE TTM 10.35

TSR TTM (23.53%)

Mkt cap ₹7.029B

ROIC —

SE Grade™

—

Value

Quality

Moat

—

1Y Price

Reference

₹226

12.64%

(16.17%)

Price above Reference Value

TTM

FYE 31 Mar INR

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026

FY2027E

Trend

10Y

Peers

6.503

Revenue₹B

—

5.112

4.996

5.777

5.995

6.503

6.822

6.20%

8.47

Revenue growth%

—

(2.26)

15.63

3.77

8.47

4.91

6.12

—

56.46

Gross margin%

—

39.87

38.68

46.28

49.75

56.46

56.43

46.28

14.22

Operating margin%

—

4.94

2.97

10.26

10.88

14.22

14.15

10.26

10.17

Net margin%

—

15.94

(2.08)

9.69

5.09

10.17

9.61

9.69

10.35

P/E ratio (avg)x

—

3.447

—

6.597

24.43

13.34

10.44

9.966

—

7.404

EV/EBITx

—

11.11

12.04

6.228

11.44

9.540

7.088

11.11

—

FCF yield (avg)%

—

FCF margin%

—

FCF / Net incomex

—

ROIC%

—

Return on equity%

—

100

—

Return on assets%

—

19.42

EPS₹

—

25.21

(3.18)

16.89

8.98

19.42

19.25

(6.32%)

—

116.15

EPS growth%

—

(112.61)

631.23

(46.81)

116.15

(0.89)

34.67

—

Bookvalue per sh₹

—

FCF per share₹

—

Dividend per sh₹

—

Div yield (avg)%

—

Payout ratio%

—

34.05

Shares (diluted)M

—

32.31

32.69

33.12

33.98

34.05

◌34.05

1.32%

(0.22)

Buyback yield%

—

(1.17)

(1.32)

(2.58)

(0.22)

◌—

(1.25)

—

D/E ratiox

—

6.845

Enterprise value₹B

—

2.808

1.787

3.692

7.459

8.819

6.845

33.12%

—

LT debt₹M

—

Peers (US$74.06M)

Cap (US$)

Amanta Healthcare…

80.74M

38.99x

ZIM Laboratories…

74.98M

326.5x

Kilitch Drugs (India)…

72.41M

28.36x

Dicot Pharma AB (publ)

74.13M

—

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

3.084

1.765

Own earn%

—

Sh yield%

(0.22)

(1.25)

Owners

Insiders/Inst%

5.46

2.22

Short interest%

—

SBC / revenue%

0.05

Record

10Y

Profitable years

4/5

Revenue growth years

3/4

EPS growth years

2/4

Dividend streakyrs

Op margin range%

3–14

$1 testx

—

Incr. ROIC%

—

Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. It offers formulations for anti-infectives, pain and analgesics, gastroenterology, rheumatology, respiratory, gynecology, and central nervous system, as well as for vitamins, minerals, and nutrition.

Growth vs revenue

Latest

Trend

4Y CAGR

Rel growth

Revenue

₹6.503B

6.20%

1.00×

Cost of revenue

₹2.831B

(2.03%)

0.72×

Operating expenses

₹2.747B

11.37%

1.21×

Revenue by region

No breakdown available

Reinvestment returns

n/m

Trend

Reinvestment rate

n/m

Return on capital

n/m

Spread over hurdle

n/m